Strategene and Takara Settle PCR Suits

Shiga, Japan: La Jolla, CA-Takara Bio and Stratagene have settled their patent disputes regarding enzyme blends used in PCR technology. Financial details were unavailable. “We believe that there are a number of competitors selling products that are covered under our patent portfolio. It is our intention to make limited licenses available and recognize resulting licensing revenue,” stated Stratagene President and CEO Joseph A. Sorge, MD.

< | >